Cite
HARVARD Citation
Seddon, B. et al. (n.d.). Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet oncology. 18 (10), pp. 1397-1410. [Online].